Skip to main content
LSL Pharma Group Inc. logo

LSL Pharma Group Inc. — Investor Relations & Filings

Ticker · LSL ISIN · CA50190N1042 TSXV Manufacturing
Open in API
Filings indexed 304 across all filing types
Latest filing 2024-03-19 Capital/Financing Update
Country CA Canada
Listing TSXV LSL

About LSL Pharma Group Inc.

https://www.groupelslpharma.com/en

LSL Pharma Group Inc. is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialized life sciences products. The company operates multiple manufacturing facilities dedicated to producing a diverse portfolio, including sterile pharmaceutical products, natural health products (NHPs), cosmetic products, food supplements, and vitamins, often in tablet and capsule formats. LSL Pharma Group functions as a Contract Development and Manufacturing Organization (CDMO) for natural and pharmaceutical segments. The company leverages its integrated capabilities to serve domestic and international markets, including strategic distribution agreements aimed at supplying high-quality pharmaceuticals to alleviate drug shortages in hospital environments.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a non-brokered private placement financing by LSL Pharma Group. It details the amount raised, the issuance of units and warrants, insider participation, and the intended use of proceeds. There are no financial statements or detailed financial performance data included. The content focuses on capital raising activities and financing updates rather than a full financial report or earnings release. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 5707 characters, which is sufficient for a detailed financing announcement but does not contain comprehensive financial data or management discussion. Hence, the classification is CAP with high confidence.
2024-03-19 English
News release - French.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a private placement financing by Groupe LSL Pharma Inc. It details the terms of the financing, including amounts, use of proceeds, and conditions. There is no financial statement or detailed financial report included, only an announcement of a capital raising event. The document is about fundraising and capital structure changes, which fits the Capital/Financing Update category. The document length is 6151 characters, which is sufficient for a detailed announcement but does not contain financial statements or analysis to qualify as an Interim Report or Annual Report. Therefore, the correct classification is Capital/Financing Update (CAP).
2024-03-07 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a private placement financing and debt conversion by LSL Pharma Group. It details the terms of the financing, use of proceeds, and regulatory approvals required. There is no financial statement or detailed financial report included, only an announcement of capital raising activities. The document length is about 5,279 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on fundraising and capital structure changes, which aligns with the Capital/Financing Update category. Therefore, the appropriate classification is CAP (Capital/Financing Update).
2024-03-07 English
Material change report - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the closing of the second tranche of a private placement of convertible debentures by Groupe LSL Pharma Inc. It includes extensive information about the terms of the debentures, interest rates, conversion rights, use of proceeds, broker commissions, regulatory approvals, and insider participation. The document references the TSX Venture Exchange (TSXV) and Canadian securities regulations (Multilateral Instrument 51-102 and Regulation 61-101). The content focuses on financing activities, specifically the issuance of convertible debentures and related capital raising details. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, management report, or governance document. The document is not a brief announcement of voting results or a director's dealing. It is not a report publication announcement since it contains substantive details about the financing transaction itself, not just a notice of report availability. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-12-15 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Material Change Report pursuant to Section 7.1 of National Instrument 51-102 Respecting Continuous Disclosure Obligations,' which is a regulatory filing format used in Canadian securities regulation. The content details the closing of the second tranche of a brokered private placement involving convertible debentures, including terms of the offering, interest rates, business objectives affecting interest rates, insider participation, and regulatory approvals. It includes detailed information about the financing transaction but does not present financial statements or comprehensive financial performance data. The document is not an annual or interim report, earnings release, or management discussion. It is a formal disclosure of a material change event related to capital raising. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-12-15 English
Report of exempt distribution (45-106F1).pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed declaration related to a securities placement with exemption, including information about the issuer, the placement, subscribers, remuneration related to the placement, and other regulatory details. It references specific regulatory rules such as Règlement 45-106 and includes detailed data on convertible debentures, placement dates, subscriber information, and remuneration paid in connection with the placement. This type of document is typical of a capital raising or financing update filing, where the company reports on a private placement or similar financing transaction. It is not an annual or interim report, audit report, earnings release, or management discussion. It is not a proxy, AGM material, or voting results. It is not a director dealing or share repurchase. The document is a formal regulatory filing about a capital raising event. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2023-12-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.